Robust Pharmacodynamic Effect of LY3202626, a Central Nervous System Penetrant, Low Dose BACE1 Inhibitor, in Humans and Nonclinical Species

BACKGROUND: The development of beta-site amyloid-beta precursor protein cleaving enzyme (BACE) 1 inhibitors for the treatment of Alzheimer’s disease requires optimization of inhibitor potency, selectivity, and brain penetration. Moreover, there is a need for low-dose compounds since liver toxicity w...

Descripción completa

Detalles Bibliográficos
Autores principales: Willis, Brian A., Lowe, Stephen L., Monk, Scott A., Cocke, Patrick J., Aluise, Christopher D., Boggs, Leonard N., Borders, Anthony R., Brier, Richard A., Dean, Robert A., Green, Steven J., James, Douglas E., Jhee, Stanford S., Lin, Qun, Lo, Albert C., May, Patrick C., Watson, Brian M., Winneroski, Leonard L., Yang, Zhixiang, Zimmer, Jennifer A., McKinzie, David L., Mergott, Dustin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2022
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842743/
https://www.ncbi.nlm.nih.gov/pubmed/35243208
http://dx.doi.org/10.3233/ADR-210037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842743/
https://www.ncbi.nlm.nih.gov/pubmed/35243208
http://dx.doi.org/10.3233/ADR-210037

Ejemplares similares